MDXH:NASDAQMDxHealth SA Analysis

MDxHealth (MDXH) is trading at $0.59, well below its 20‑day (0.72), 50‑day (1.55) and 200‑day (3.17) SMAs, signaling a strong bearish price trend. However, the RSI of 19 indicates the stock is deeply oversold and the MACD histogram has turned positive, giving a bullish signal. Volatility is extreme at 205% over the last 30 days and beta is 1.99, suggesting the share will continue to swing sharply. On the fundamentals side, revenue has risen 12.7% YoY to $111M with a healthy gross margin of 63.7%, yet operating and profit margins remain negative (‑26.7% and ‑29.9% respectively) and cash flow is negative, while total debt ($106M) more than doubles cash on hand ($43M).
Recent news shows the company exited its Resolve UTI business and closed a Texas lab to sharpen focus on prostate‑cancer diagnostics, reporting Q1 2026 core revenue of $23.9M (up 11% YoY) and a gross margin of 62.9%. Although the earnings beat was missed and guidance remains cautious, analysts rate the stock as a "buy" with a median price target of $3, implying a potential upside of over 400%.